基于加速镜像下降优化和三维聚合残余网络的阿尔茨海默氏病诊断
Yue Tu1, Shukuan Lin1, Jianzhong Qiao1
1Department of Computer Science and Engineering, Northeastern University, Shenyang 110819, China.
Sensors (Basel, Switzerland)
|November 14, 2023
概括
这项研究引入了一种新的深度学习方法,用于使用3D脑部扫描更快,更准确地诊断阿尔茨海默病 (AD). 这种新的方法提高了诊断的准确性,并大大减少了计算机辅助诊断模型的培训时间.
科学领域:
- 神经科学和医学成像学
- 医疗保健中的人工智能
- 计算诊断的诊断 计算诊断的诊断
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经精神疾病,影响老年人,目前没有针对性的治疗方法.
- 早期和快速诊断AD对于及时干预和缓解疾病进展至关重要.
- 现有的3D AD图像分析深度学习模型存在缓慢的融合,梯度问题和局部最佳值问题,导致准确性差,训练时间长.
研究的目的:
- 开发一个新的3D聚合残留网络 (ARCNN) 用于阿尔茨海默病的诊断.
- 引入一个无偏的下坡加速镜子下降 (SAMD) 优化算法,以提高训练速度和准确性.
- 为了解决现有的计算机辅助诊断 (CAD) 模型对3DAD成像的局限性.
主要方法:
- 提出了一种新的无偏向的下梯次加速镜像下降 (SAMD) 优化算法,以加快网络训练并避免局部优化.
- 开发了一个3D聚合残余网络架构 (ARCNN) 用于处理3D阿尔茨海默病图像.
- 使用ADNI数据集对阿尔茨海默病与正常控制 (AD与NC) 以及显著轻度认知障碍与渐进轻度认知障碍 (sMCI与pMCI) 任务进行训练和评估的ARCNN模型.
主要成果:
- 拟议的SAMD算法与现有的梯度下降算法相比,显示出更好的收.
- 使用SAMD训练的ARCNN模型实现了AD诊断的95.4%准确率和MCI诊断的79.9%准确率.
- 与梯度下降方法相比,SAMD算法在AD诊断模型中平均减少了约19%的融合时间.
结论:
- 新的3D ARCNN与SAMD优化算法相结合,显著提高了阿尔茨海默病诊断的准确性和速度.
- 这种通过改进的算法优化AD诊断培训过程的开创性方法为早期检测提供了有前途的工具.
- 增强的诊断性能和加快的培训时间为阿尔茨海默病检测的临床应用提供了显著的潜力.
相关概念视频
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197


